Determining the molecular heterogeneity of leukemia propagating cells in childhood AML

确定儿童 AML 中白血病增殖细胞的分子异质性

• 批准号: nhmrc : 1054482
• 负责人: Dr Elizabeth Kruse
• 金额: $ 28.05万
• 依托单位: The Walter and Eliza Hall Institute of Medical Research
• 依托单位国家: 澳大利亚
• 项目类别: Early Career Fellowships
• 财政年份: 2013
• 资助国家: 澳大利亚
• 起止时间: 2013-01-01 至 2019-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/determining-molecular-heterogeneity-childhood-aml/112394
• 关键词: Determining; molecular; heterogeneity; leukemia; propagating

Current treatments for AML are initially effective at killing the majority of leukemic cells, but the disease often comes back (relapses) due to rare cells that escape treatment and can regenerate the cancer (called leukemic stem cells or LSC for short). This project aims to determine if an individual patient has one, or many kinds of LSC and which kind of LSC is most likely to cause relapse. We believe that this knowledge will lead to new treatments that can target the cells that cause relapse.

目前治疗AML的方法最初在杀死大多数白血病细胞方面是有效的，但由于罕见的细胞逃脱治疗并能再生癌症(简称白血病干细胞或LSC)，这种疾病经常复发。该项目旨在确定单个患者是否患有一种或多种LSC，以及哪种LSC最有可能导致复发。我们相信，这一知识将导致新的治疗方法，可以针对导致复发的细胞。